Unbiased Analysis of Today's Healthcare Issues
The Academy of Managed Care Pharmacy (AMCP) held an interesting webinar titled “5 Years of ICER – Insights and Impact on Payers“. Some highlights form the presentation. Most relevant information Jeremy Lee from MedImpact–a pharmacy benefits manager (PBM)–noted that their Pharmacy and Therapeutics (P&T) committee used four key pieces of evidence when making coverage and…
According to a paper by Stevens et al. (2020), the answer is ‘yes’. One clear reason why it would change is if the drug’s price changes. Even if that is not the case, however, the drug may be more or less effective over time. For instance, physicians may improve their ability to manage side effects…
Entities such as the Panel on Cost Effectiveness in Health and Medicine have argued that we should include the societal perspective when measuring the value of a certain treatment through cost-effectiveness analysis (CEA). However, societal perspective is not always the one used. Further, even when the societal perspective is taken, this is often limited to…
My colleagues Jeroen Jansen, Devin Incerti along with Jeff Curtis think so. In JMCP they write: In the United States, there is an increased interest to understand the value of health technologies. Cost-effectiveness analysis is arguably the most appropriate framework to quantify value and to inform reimbursement decision making regarding medical interventions; however, a thorough…
To find out the answer to this question, check out a live webinar on Wednesday, March 13th at 1:30pm EDT led by Dr. Anupam Jena, MD, PhD. Dr. Jena is a Harvard Professor and Precision Health Economics Scientific Advisor. In this unique one-hour webinar, Dr. Jena will outline a broader framework for assessing value to improve identification of not…